Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.
Two cases suggest that Viread alone may not be enough to prevent HIV through pre-exposure prophylaxis (PrEP)
Two and a half years into a PrEP program in San Francisco, none of the more than 600 gay men taking Truvada have contracted the HIV.
People with hepatitis B can safely take Truvada as PrEP, as it does not lead to liver inflammation â€œflaresâ€ or other health probl...
Among HIV-positive people, it is preferable to treat hepatitis B with a two-drug regimen rather than with monotherapy.
Harvoni yielded a 96 percent cure rate among people with genotype 1 of hepatitis C, as well as a small number of those with genotype 4.
Evidence of sexual acquisition of hepatitis C among gay men receiving PrEP at a San Francisco clinic has prompted a call for routine...
Viread (tenofovir) is highly effective at suppressing hepatitis B, even after an eight-year period.
Twelve weeks of Gilead Sciences newly approved Harvoni cured nearly all people with genotype 1 of hepatitis C who were coinfected with HIV in...
AbbVie’s ’3D’ regimen has shown high cure rates in treating genotype 1 of hepatitis C among those coinfected with HIV
With $3.48 billion in sales of the hepatitis C drug Sovaldi, Gilead Sciences reported a second-quarter revenue of $6.53 billion.
Sovaldi (sofosbuvir) and ribavirin cured between 84 percent and 91 percent of people coinfected with HIV and genotypes 1 through 4 of hep C.
The Sovaldi/ledipasvir combination pill to treat hepatitis C does not have a clinically significant impact on five common HIV antiretrovirals.
Early results of Merck’s combination hepatitis C therapy showed comparable safety between those with or without HIV, plus near-perfect cure ra...
The HIV antiretroviral Viread (tenofovir) is highly effective in combating both HIV and hepatitis B among those coinfected with both viruses
The HIV antiretrovirals Viread (tenofovir) and Emtriva (emtricitabine), can suppress hepatitis B in three-quarters of those with ?immune-toler...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.